Nebenwirkungen · Lazcluze
Lazcluze 80 mg film-coated tablets Lazcluze 240 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 12
HOS-151430 · Präparat HOS-100535
Hepatotoxicity-related reactions occurred in 47% of patients treated with lazertinib in combination with amivantamab. Most events were Grade 1-2, with Grade 3-4 hepatotoxicity occurring in 9% of patients. Most events were related to elevations of serum transaminases (36% alanine aminotransferase increased and 29% aspartate aminotransferase increased). Most patients with elevations of transaminases were able to continue study treatment without modification of study treatment while a small number were managed with a dose interruption or with a dose reduction. There were no cases of liver failure or fatal cases of hepatotoxicity in clinical studies with lazertinib in combination with amivantamab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-12T16:08:31Z · SHA-256 1473f5edd2523c74fb17bb2ceb92aa90b2ceba65343d261aad9177ebf723dcbf · Passage 591dc8b46c6ff17736c56deacfdf6fd9dcd085fad71aa927d618d6c686454134 · Zeichen 9177–9879 im Abschnitt